You are here: Industry Insights > Actemra

News List

Roche response to COVID-19 pandemic worldpharmanews
March 27, 2020
Roche Group, provided an update on the various actions the company is taking to address the COVID-19 pandemic.
FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients pharmaceutical-business-review
March 25, 2020
Genentech has secured approval in the US to go ahead with the COVACTA trial to assess the use of its rheumatoid arthritis drug (RA drug) Actemra (tocilizumab) in COVID-19 patients.
Genentech secures FDA approval to trial Actemra for Covid-19 pharmaceutical-technology
March 25, 2020
Roche unit Genentech has received US Food and Drug Administration (FDA) approval to conduct a Phase III clinical trial of its rheumatoid arthritis drug Actemra (tocilizumab) ...
Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia worldpharmanews
March 23, 2020
Roche is working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration ...
Roche to start Phase III trial of Actemra in Covid-19 patients pharmaceutical-technology
March 20, 2020
Roche has collaborated with the US Food and Drug Administration (FDA) to conduct a Phase III clinical trial of Actemra/RoActemra (tocilizumab) in hospitalised adults with severe Covid-19 pneumonia.
China approves use of Roche arthritis drug for some Covid-19 patients expresspharma
March 05, 2020
Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients who show serious lung damage.
Mycenax’s Actemra biosimilar edges closer to approval pharmaphorum
January 02, 2019
Mycenax’s biosimilar of Roche’s Actemra (tocilizumab), LusiNEX, has been shown to match its originator’s profile in a phase I PK trial, meaning it is on track to become the first approved biosimilar for the drug.
FDA Approves Subcutaneous Formulation of Actemra for use in Active Polyarticular Juvenile Idiopathic Arthritis drugs
May 17, 2018
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved the subcutaneous (SC) formulation of Actemra® (tocilizumab)

Previous page 1 2 Next page